Headerlogotextwithshieldsshadowed
Dan Duda
Director of Translational Research in GI Radiation Oncology
Duda Lab

Duda Lab Research

Duda_HMS_CV.pdf

Current Research Goals

Over the last decade and a half, I have built a productive Liver Cancer Research Program within the Steele Laboratories for Tumor Biology. The translational goal of this program is to increase the durability of response to the most effective available therapies. The approach is to identify new cellular and molecular mechanisms of local and metastatic tumor progression and treatment resistance and validate them as new targets for combination therapies for cancer.

To this end, my group is studying the activity of antiangiogenic drugs, antifibrotic drugs or radiotherapy approaches in combination with immunotherapy. In preclinical studies, we are employing models that reproduce the hallmarks of human cancers (i.e., genetically engineered models of primary hepatocellular carcinoma and cholangiocarcinoma, and metastatic pancreatic, breast and prostate carcinomas). In parallel, in clinical studies in cancer patients, we are conducting correlative studies of biomarkers of response to the same approaches. My research efforts are currently supported by grants from Federal sources – US Department of Defense (DoD) and National Cancer Institute (NCI) – and Foundations, and by agreements with Industry partners (Bayer, Exelixis and BMS).

Track Record and Service

I have authored over 240 publications so far, of which 140+ are original reports, including in basic research journals such as Nature, Nature Medicine, Nature Biotechnology, Nature Genetics, Cell, Cancer Cell, Science Translational Medicine, Gut and Hepatology as well as in clinical journals such as the Journal of Clinical Oncology, Nature Precision Oncology and JAMA Oncology. Over the last 2 decades, I have been invited to present our results at over 200 local, national and international meetings, including in Grand Rounds (Harvard, Mayo Clinic, Yale, Fred Hutchinson Cancer Center), Plenary and State-of-the-art Talks (AACR, IASGO) and Keynote Lectures. For my work, I have received several awards, including from the AACR, Cancer Research Institute (CRI), IASGO, and MGH. I was elected as an Honorary Member of the Academy of Medical Sciences of Romania in 2012, and as a member of the College of Fellows of the American Institute for Medical and Biomedical Engineering (AIMBE) in 2020.

I have been  serving as chartered or ad-hoc Member, and Chair or co-Chair of US NCI, American Cancer Society (ACS), US Department of Defense (DOD), and Belgium FWO Med4 panels since 2012. I am a  Founding Editor of the journal Surgery, Gastroenterology and Oncology, a Senior Associate Editor of the International Journal of Radiation Oncology*Biology*Physics, and an Editorial Board member for several other journals, including Clinical & Translational Radiation Oncology, Journal of Hepatocellular Carcinoma and Cancers. I am serving as the Secretary General of the IASGO since 2015. In addition, I am a member of the American Association for the Study of Liver Diseases (AASLD) Liver Fibrosis Special Interest Group and of the NCI Hepatobiliary Task Force for Immuno-Oncology Biomarkers. 

Teaching

I am teaching tumor biology and translational oncology through daily supervision of 50+ postdoctoral research fellows, and graduate and undergraduate students. As a passionate supporter of the IASGO’s mission to globalize the best medical practice and knowledge all over the world, I have been coordinating, teaching and directing Postgraduate Courses in 28 countries in Asia, Europe, Africa and the Americas, since 2013. I have also taught nationally in ASTRO and RTOG translational meetings for residents and clinicians and locally in the MIT-HMS HST Program since 2005. I have been coordinating a research exchange student program with University of Muenster, Germany since 2015, and I have been directing an Annual Course titled “Methods in Biomedical Engineering, Tumor Biology and Immunology” at MGH since 2004.  

Education and Academic Appointments

I obtained a DMD from the University of Medicine Iasi, Romania in 1993, and earned a PhD in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001. After graduation, I pursued postdoctoral training with Professor Rakesh K. Jain in the Steele Laboratories for Tumor Biology, Department of Radiation Oncology, MGH and Harvard Medical School in Boston. I became a Junior Faculty member (Instructor) in 2004, and then rose through the ranks to Full Investigator at MGH Research Institute in 2016 and Associate Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School in 2012. In 2016, I was appointed as the Director of Translational Research in Gastrointestinal Radiation Oncology at MGH. In 2020, I received the honorary degree "Doctor Honoris Causa" from the University of Medicine Iasi, Romania, my Alma Mater.

(For more information, see full CV above.) 

Lab News

Improving treatment of liver cancer

Steele researchers discover a promising approach to inhibiting a less frequent but highly treatment-refractory liver cancer

Press release

Article URL

New strategy for immunotherapy of liver cancer

Judiciously dosed regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma (HCC). 

Article URL


Dr. Dan G. Duda elected to the AIMBE College of Fellows – Class of 2020

Dan G. Duda, DMD, PhD, Director of Translational Research in GI Radiation Oncology, Department of Radiation Oncology, has been inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Election is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top 2% of medical and biological engineers.

AIMBE News Release

Shuichi Aoki awarded the 2018 Tommy J. West Memorial Research Fellowship

Dr. Shuichi Aoki was awarded the 2018 Tommy J. West Memorial Research Fellowship by the Cholangiocarcinoma Foundation for the project "Role of PlGF/Nrp1 Pathway in Intrahepatic Cholangiocarcinoma Cell Survival, Tumor-associated Fibrosis and Abnormal Vasculature".

Cholangiocarcinoma Foundation

News Release

Dr. Duda selected as the an honoree of The One Hundred by Mass General Cancer Center

Dr. Dan Duda was selected as an honoree of the one hundred in 2015. Created and supported by the Mass General Cancer Center, the one hundred is an awareness and fundraising initiative that celebrates hope in the cancer community. Each year, it honors 100 Everyday Amazing individuals and groups – caregivers, researchers, philanthropists, advocates and volunteers from around the globe – whose commitment to the fight against cancer inspires all to take action. Selection as an honoree of the one hundred is one of the highest forms of recognition awarded by Mass General Cancer Center.

MGH Feed

Facebook Feed

Duda Lab Careers

Postdoctoral Fellows

Investigator: Duda, Dan
Date Posted: 2021-02-07
Description
The Duda Lab is currently seeking postdoctoral applicants with expertise in molecular biology and cell biology. The project requires a motivated, independent researcher to carry out a project aimed at understanding the molecular underpinnings of liver, pancreatic and breast cancer progression and response and resistance to immunotherapies.
Requirements
Applicants should send a CV, career statement and three letters of reference to: Dan G. Duda, DMD, PhD Associate Professor Massachusetts General Hospital & Harvard Medical School 100 Blossom Street, Cox Building 734, Boston, MA 02114 duda@steele.mgh.harvard.edu

Selected Publications (from total of 191)

Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Gut. 2021;:ePub - PMID: 33431577 - DOI: 10.1136/gutjnl-2020-322493
Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
J Immunother Cancer. 2020;8(2):ePub - PMID: 33234602 - PMCID: PMC7689089 - DOI: 10.1136/jitc-2020-001435
Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG
Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Clin Cancer Res. 2020;26(23):6158-6167 - PMID: 32878766 - DOI: 10.1158/1078-0432.CCR-20-1310
Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - PMCID: PMC7456461 - DOI: 10.1038/s41587-019-0404-8
Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, Duda DG, Xie T, Farokhzad OC, Shi J
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes <i>p53</i>-deficient cancers to mTOR inhibition.
Sci Transl Med. 2019;11(523):ePub - PMID: 31852795 - PMCID: PMC7024563 - DOI: 10.1126/scitranslmed.aaw1565
Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG
Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC.
Hepatology. 2020;71(4):1247-1261 - PMID: 31378984 - PMCID: PMC7000304 - DOI: 10.1002/hep.30889
Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
NPJ Precis Oncol. 2018;2:22 - PMID: 30374460 - PMCID: PMC6194077 - DOI: 10.1038/s41698-018-0065-y
Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PKH, Chung AYF, Ooi LLPJ, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov L, Gordan R, Rozen SG, Shibata T, Pairojkul C, Teh BT, Tan P
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Cancer Discov. 2017;7(10):1116-1135 - PMID: 28667006 - PMCID: PMC5628134 - DOI: 10.1158/2159-8290.CD-17-0368
Popp I, Grosu AL, Niedermann G, Duda DG
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.
Radiother Oncol. 2016;120(2):185-94 - PMID: 27495145 - DOI: 10.1016/j.radonc.2016.07.013
Hato T, Zhu AX, Duda DG
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Immunotherapy. 2016;8(3):299-313 - PMID: 26865127 - PMCID: PMC5619018 - DOI: 10.2217/imt.15.126
Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Hepatology. 2015;61(5):1591-602 - PMID: 25529917 - PMCID: PMC4406806 - DOI: 10.1002/hep.27665
Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG
Quantum dot/antibody conjugates for in vivo cytometric imaging in mice.
Proc Natl Acad Sci U S A. 2015;112(5):1350-5 - PMID: 25605916 - PMCID: PMC4321304 - DOI: 10.1073/pnas.1421632111
Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG
A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys. 2014;89(4):830-8 - PMID: 24867540 - PMCID: PMC4791180 - DOI: 10.1016/j.ijrobp.2014.03.034
Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG
Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.
Hepatology. 2014;59(4):1435-47 - PMID: 24242874 - PMCID: PMC3966948 - DOI: 10.1002/hep.26790
Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK
Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci U S A. 2010;107(50):21677-82 - PMID: 21098274 - PMCID: PMC3003109 - DOI: 10.1073/pnas.1016234107
15